• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗补助肝硬化人群中肝细胞癌的监测。

Surveillance for hepatocellular carcinoma in a Medicaid cirrhotic population.

机构信息

Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.

出版信息

J Clin Gastroenterol. 2013 Sep;47(8):713-8. doi: 10.1097/MCG.0b013e318286fd97.

DOI:10.1097/MCG.0b013e318286fd97
PMID:23442840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3745802/
Abstract

GOALS

To estimate the hepatocellular carcinoma surveillance in the Medicaid cirrhotic population.

BACKGROUND

Most studies predate 2005 American Association for the Study of Liver Diseases surveillance recommendations and do not examine the primary target population, cirrhotics.

STUDY

From 2006 to 2007, we identified adults with at least 1 cirrhosis International Classification of Disease code and 15 months of continuous enrollment in North Carolina Medicaid, recording claims for abdominal ultrasound, computed tomography, magnetic resonance imaging, and α-fetoprotein testing. We used multivariable logistic regression to identify factors independently associated with imaging.

RESULTS

A total of 5061 subjects were identified: mean age 54 years, 54% male patients, 35% African American, 56% white. Cirrhosis risk factors were alcohol (59%), hepatitis C (30%), hepatitis B (4%), others (18%), and unknown (24%). Only 26% underwent at least 1 imaging test. Just 12% of those not hospitalized or seen in an emergency department underwent any imaging test. Care in an academic facility, younger age, female sex, viral hepatitis, and Medicare coinsurance were positively associated with imaging. Twenty-one percent saw a gastroenterologist, which increased the odds of undergoing imaging (odds ratio, 2.81; 95% confidence interval, 2.32-3.41), whereas primary care visits did not (odds ratio, 0.94; 95% confidence interval, 0.76-1.16).

CONCLUSIONS

Only a quarter of North Carolina Medicaid cirrhotics underwent abdominal imaging over a 15-month period, and many tests may have been conducted without surveillance intent. Gastroenterology visits nearly tripled the odds of imaging, but primary-care visits had no effect. Efforts to improve surveillance rates in cirrhotic patients should target primary care and increased access to subspecialty care.

摘要

目的

估计医疗补助肝硬化人群中的肝细胞癌监测情况。

背景

大多数研究都早于 2005 年美国肝病研究协会的监测建议,并且没有检查主要目标人群,即肝硬化患者。

研究

我们从 2006 年到 2007 年,在北卡罗来纳州医疗补助中确定了至少有 1 次肝硬化国际疾病分类代码和 15 个月连续入组的成年人,记录腹部超声、计算机断层扫描、磁共振成像和甲胎蛋白检测的索赔。我们使用多变量逻辑回归来确定与成像独立相关的因素。

结果

共确定了 5061 名受试者:平均年龄 54 岁,54%为男性患者,35%为非裔美国人,56%为白人。肝硬化的危险因素为酒精(59%)、丙型肝炎(30%)、乙型肝炎(4%)、其他(18%)和未知(24%)。只有 26%的患者至少进行了 1 次影像学检查。只有 12%的未住院或未在急诊就诊的患者进行了任何影像学检查。在学术机构接受治疗、年龄较小、女性、病毒性肝炎和医疗保险共付额与影像学检查呈正相关。21%的患者看了胃肠病学家,这增加了进行影像学检查的几率(比值比,2.81;95%置信区间,2.32-3.41),而初级保健就诊没有(比值比,0.94;95%置信区间,0.76-1.16)。

结论

在 15 个月的时间里,只有四分之一的北卡罗来纳州医疗补助肝硬化患者接受了腹部影像学检查,并且许多检查可能是在没有监测目的的情况下进行的。胃肠病学就诊几乎使影像学检查的几率增加了两倍,但初级保健就诊没有影响。为提高肝硬化患者的监测率,应针对初级保健并增加获得专科医疗的机会。

相似文献

1
Surveillance for hepatocellular carcinoma in a Medicaid cirrhotic population.医疗补助肝硬化人群中肝细胞癌的监测。
J Clin Gastroenterol. 2013 Sep;47(8):713-8. doi: 10.1097/MCG.0b013e318286fd97.
2
Racial, social, and clinical determinants of hepatocellular carcinoma surveillance.肝细胞癌监测的种族、社会和临床决定因素。
Am J Med. 2015 Jan;128(1):90.e1-7. doi: 10.1016/j.amjmed.2014.07.027. Epub 2014 Aug 10.
3
Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study.在常规实践中对慢性乙型肝炎的初始评估、长期监测和肝细胞癌监测:一项全美范围的研究。
Am J Gastroenterol. 2021 Sep 1;116(9):1885-1895. doi: 10.14309/ajg.0000000000001271.
4
Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance.商业健康保险覆盖的肝硬化患者中的肝细胞癌监测
J Clin Gastroenterol. 2016 Mar;50(3):258-65. doi: 10.1097/MCG.0000000000000411.
5
Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey.美国肝硬化患者肝细胞癌筛查:一项全国性调查结果
Am J Gastroenterol. 1999 Aug;94(8):2224-9. doi: 10.1111/j.1572-0241.1999.01297.x.
6
Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.在全国肝硬化患者样本中识别肝细胞癌监测的障碍。
Hepatology. 2017 Mar;65(3):864-874. doi: 10.1002/hep.28765. Epub 2016 Oct 5.
7
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.美国丙型肝炎病毒感染者肝癌监测的利用。
Ann Intern Med. 2011 Jan 18;154(2):85-93. doi: 10.7326/0003-4819-154-2-201101180-00006.
8
Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis.非酒精性脂肪性肝炎肝硬化患者的肝细胞癌筛查不足。
J Clin Gastroenterol. 2019 Feb;53(2):142-146. doi: 10.1097/MCG.0000000000001075.
9
Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers.基层医疗服务提供者对肝细胞癌的监测不足及认识欠缺。
Clin Gastroenterol Hepatol. 2015 Apr;13(4):799-804. doi: 10.1016/j.cgh.2014.07.056. Epub 2014 Aug 10.
10
[Screening for hepatocellular carcinoma in cirrhotic patients].[肝硬化患者肝细胞癌的筛查]
Gastroenterol Clin Biol. 2000 May;24(5 Pt 2):B92-4.

引用本文的文献

1
Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis at US Safety-Net Health Systems.美国安全网医疗系统中肝硬化患者的肝细胞癌监测
Clin Transl Gastroenterol. 2025 Jun 25;16(8):e00877. doi: 10.14309/ctg.0000000000000877. eCollection 2025 Aug 1.
2
Hepatocellular carcinoma national burden across different geographical regions in the United States between 2001 and 2020.2001年至2020年美国不同地理区域肝细胞癌的全国负担
World J Methodol. 2024 Dec 20;14(4):95598. doi: 10.5662/wjm.v14.i4.95598.
3
Clinician-Level Knowledge and Barriers to Hepatocellular Carcinoma Surveillance.临床医生对肝细胞癌监测的认知和障碍。
JAMA Netw Open. 2024 May 1;7(5):e2411076. doi: 10.1001/jamanetworkopen.2024.11076.
4
Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.肝细胞癌监测——利用、障碍以及病因变化的影响。
Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):797-809. doi: 10.1038/s41575-023-00818-8. Epub 2023 Aug 3.
5
Adherence to guideline-directed hepatocellular carcinoma screening: A single-center US experience.遵循指南指导的肝细胞癌筛查:美国单中心经验
World J Hepatol. 2023 Mar 27;15(3):410-418. doi: 10.4254/wjh.v15.i3.410.
6
Patient-, Provider-, and System-Level Barriers to Surveillance for Hepatocellular Carcinoma in High-Risk Patients in the USA: a Scoping Review.美国高危人群肝癌监测的患者、提供者和系统层面障碍:范围综述。
J Gastrointest Cancer. 2023 Jun;54(2):332-356. doi: 10.1007/s12029-022-00851-x. Epub 2022 Jul 26.
7
Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C.丙型肝炎治愈患者的肝细胞癌监测、发病率和肿瘤倍增时间。
Cancer Med. 2022 May;11(9):1995-2005. doi: 10.1002/cam4.4508. Epub 2022 Mar 9.
8
Epidemiology and Outcomes of Hospitalizations Due to Hepatocellular Carcinoma.肝细胞癌住院治疗的流行病学与结局
Cureus. 2021 Dec 1;13(12):e20089. doi: 10.7759/cureus.20089. eCollection 2021 Dec.
9
Development and validation of artificial intelligence to detect and diagnose liver lesions from ultrasound images.开发和验证人工智能以从超声图像中检测和诊断肝脏病变。
PLoS One. 2021 Jun 8;16(6):e0252882. doi: 10.1371/journal.pone.0252882. eCollection 2021.
10
Epidemiology and surveillance for hepatocellular carcinoma: New trends.肝癌的流行病学和监测:新趋势。
J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025.

本文引用的文献

1
Screening for liver cancer: the rush to judgment.肝癌筛查:仓促下结论。
Ann Intern Med. 2012 Mar 6;156(5):387-9. doi: 10.7326/0003-4819-156-5-201203060-00012.
2
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.美国丙型肝炎病毒感染者肝癌监测的利用。
Ann Intern Med. 2011 Jan 18;154(2):85-93. doi: 10.7326/0003-4819-154-2-201101180-00006.
3
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.慢性丙型肝炎病毒感染患者中 HCC 和肝硬化的患病率不断增加。
Gastroenterology. 2011 Apr;140(4):1182-1188.e1. doi: 10.1053/j.gastro.2010.12.032. Epub 2010 Dec 22.
4
Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound.使用超声造影检测肝硬化肝脏中的局灶性肝病变
World J Radiol. 2009 Dec 31;1(1):25-36. doi: 10.4329/wjr.v1.i1.25.
5
Surveillance for hepatocellular carcinoma: development and validation of an algorithm to classify tests in administrative and laboratory data.肝细胞癌监测:在行政和实验室数据中分类检测的算法的制定和验证。
Dig Dis Sci. 2010 Nov;55(11):3241-51. doi: 10.1007/s10620-010-1387-y. Epub 2010 Sep 16.
6
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.美国肝硬化患者中肝细胞癌监测的应用。
Hepatology. 2010 Jul;52(1):132-41. doi: 10.1002/hep.23615.
7
Colorectal cancer screening barriers and facilitators in older persons.老年人结直肠癌筛查的障碍和促进因素。
Prev Med. 2010 Jan-Feb;50(1-2):3-10. doi: 10.1016/j.ypmed.2009.12.005. Epub 2009 Dec 16.
8
Recommendation for and receipt of cancer screenings among medicaid recipients 50 years and older.50岁及以上医疗补助受助者的癌症筛查建议及接受情况
Arch Intern Med. 2008 Oct 13;168(18):2014-21. doi: 10.1001/archinte.168.18.2014.
9
The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases.退伍军人事务部行政数据库中病毒性肝炎和慢性肝病诊断的有效性。
Aliment Pharmacol Ther. 2008 Feb 1;27(3):274-82. doi: 10.1111/j.1365-2036.2007.03572.x. Epub 2007 Nov 8.
10
Deaths: final data for 2004.死亡情况:2004年最终数据。
Natl Vital Stat Rep. 2007 Aug 21;55(19):1-119.